FDA Approved: REPATHA — Supplemental Application (Amgen USA Inc.)

View source ↗

Summary

The FDA page indicates a supplemental application for Repatha (evolocumab) submitted by Amgen USA Inc.; the submission status is AP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• Repatha (Evolocumab)

Snippet

SUPPL AP for REPATHA (EVOLOCUMAB)